Revance to Participate in Upcoming Investor Conferences
February 22 2017 - 4:05PM
Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing botulinum toxin products for use in aesthetic
and therapeutic indications, today announced that the company will
participate in two upcoming investor conferences.
Revance management is scheduled to present at the Cowen and
Company 37th Annual Health Care Conference in Boston, MA on
Tuesday, March 7 at 10:00am ET.
Revance management is also scheduled for a fireside chat at the
Barclays Capital Global Healthcare Conference 2017 in Miami, FL on
Tuesday, March 14 at 3:20pm ET.
Interested parties can access the live audio webcast for both of
these conferences from the Investor Relations section of the
company's website at www.revance.com. The webcast replay will be
available after the conclusion of the live presentation for
approximately 30 days.
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is
committed to the advancement of remarkable science. The company is
developing a portfolio of products for aesthetic medicine and
underserved therapeutic specialties, including dermatology,
orthopedics and neurology. Revance’s science is based upon a
proprietary peptide technology, which when combined with active
drug molecules, may help address current unmet needs. Revance’s
initial focus is on developing DaxibotulinumtoxinA, the company’s
highly purified botulinum toxin, for a broad spectrum of aesthetic
and therapeutic indications, including facial wrinkles and muscle
movement disorders.
The company’s lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis with the
potential to be the first long-acting neurotoxin. The company holds
worldwide rights for all indications of RT002 injectable and RT001
topical and the pharmaceutical uses of its proprietary peptide
technology platform. More information on Revance may be found
at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170222006396/en/
Investors:Revance TherapeuticsJeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellanAmi Bavishi,
212-213-0006abavishi@burnsmc.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024